Uric acid level as a risk factor for the adverse course of COPD and acute coronary syndrome (ACS)
https://doi.org/10.24884/1609-2201-2024-103-4-20-25
Abstract
The article presents current data on the effect of elevated uric acid levels on the course and prognosis of such significant diseases as acute coronary syndrome (ACS) and chronic obstructive pulmonary disease (COPD). The authors have convincingly shown that hyperuricemia (HY) is associated with higher mortality and a higher frequency of cardiovascular events after ACS, as well as significantly worsens the course of COPD. Thus, the level of uric acid can be considered as a marker for the prognosis of the course and risk of progression of these diseases, considering of its availability, is of interest for practical medicine.
About the Authors
E. A. Bruchkus
Pavlov University
Russian Federation
Russian Federation
Elena A. Bruchkus - physician of the highest category, head of the Cardiology Department No. 2 of the Research Institute of Rheumatology and Allergology.
Saint Petersburg
V. V. Kulik
Pavlov University
Russian Federation
Russian Federation
Vladislav V. Kulik - general practitioner, assistant of the Department of General Medical Practice (Family Medicine).
6‒8, L’va Tolstogo str., Saint Petersburg, 197022
S. I. Kirpichnikov
Pavlov University
Russian Federation
Russian Federation
Sergey I. Kirpichnikov - general practitioner, assistant of the Department of General Medical Practice (Family Medicine).
Saint Petersburg
N. L. Shaporova
Pavlov University
Russian Federation
Russian Federation
Natalia L. Shaporova - Dr. of Sci. (Med.), Professor, Head of the Department of General Medical Practice (Family Medicine).
St. Petersburg
References
1. Maloberti A., Giannattasio C., Bombelli M. et al. Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) project. High Blood Pressure and Cardiovascular Prevention. 2020;27(2):121–128. https://doi.org/10.1007/s40292-020-00368-z.
2. Shalnova S. A., Deev A. D., Artamonov G. V. et al. Hyperuricemia and its correlates in the Russian population (results of esse-rf epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):153–159. (In Russ.). https://doi.org/10.20996/1819-6446-2014-10-2-153-159.
3. Golovach I. Yu., Yehudina Y. D., Ter-Vartanian S. Kh. Asymptomatic hyperuricemia: secret relationships, invisible effects and potential complications. Rheumatology Science and Practice. 2020;58(6):725–733. (In Russ.). https://doi.org/10.47360/1995-4484-2020-725-733.
4. Libov I. A., Moiseeva Yu. N., Komarova A. G. Hyperuricemia as a risk factor for cardiovascular events in hypertensive patients. Russian Journal of Cardiology. 2022;27(9):5194. (In Russ.). https://doi.org/10.15829/1560-4071-2022-5194.
5. Freilich M., Arredondo A., Zonnoor S. L., McFarlane I. M. Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions. Cureus. 2022;14(3):e23582. https://doi.org/10.7759/cureus.
6. Grassi G., Vanoli J., Facchetti R., Mancia G. Uric acid, hypertensive phenotypes, and organ damage: data from the Pamela study. Curr Hypertens Rep. 2022;24(2):29–35. https://doi.org/10.1007/s11906-022-01174-9.
7. Li M., Hu X., Fan Y. et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality: a systematic review and dose-response meta-analysis. Sci Rep. 2016;6:19520. https://doi.org/10.1038/srep19520.
8. Gao Z., Shi H., Xu W. et al. Hyperuricemia increases the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Endocrinol. 2022;2022:8172639. https://doi.org/10.1155/2022/8172639.
9. Raya-Cano E., Vaquero-Abellán M., Molina-Luque R. et al. Association between metabolic syndrome and uric acid: a systematic review and meta-analysis. Sci Rep. 2022;12(1):18412. https://doi.org/10.1038/s41598-022-22025-2.
10. Gonçalves D. L. N., Moreira T. R., da Silva L. S. A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease. Sci Rep. 2022;12(1):6251. https://doi.org/10.1038/s41598-022-10118-x.
11. Borghi C., Agabiti-Rosei E., Johnson R. J. et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11. https://doi.org/10.1016/j.ejim.2020.07.006.
12. Kikuchi A., Kawamoto R., Ninomiya D., Kumagi T. Hyperuricemia is associated with all-cause mortality among males and females: findings from a study on Japanese community-dwelling individuals. Metabolism Open. 2022;14:100186. https://doi.org/10.1016/j.metop.2022.100186.
13. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2023. URL: https://goldcopd.org/ (accessed: 20.12.24).
14. Masannagari P., Chaitra H. B., Choudhary A., Rajashekaraiah V. Influence of uric acid on erythrocytes subjected to H₂O₂-induced oxidative stress. Appl In Vitro Toxicol. 2023;9(2):37–43. https://doi.org/10.1089/aivt.2023.0001.
15. Ma P., Zhao M., Li Y. et al. The protective effects of uric acid against myocardial ischemia via the Nrf2 pathway. Eur J Pharmacol. 2023;959: 176062. https://doi.org/10.1016/j.ejphar.2023.176062.
16. Galunska B., Paskalev D., Yankova T., Chankova P. The biochemical Ianus: uric acid oxidant or antioxidant? Nephrology. 2004;8(4):25–31. URL: https://cyberleninka.ru/article/n/dvulikiy-yanus-biohimii-mochevaya-kislota-oksidant-ili-antioksidant (accessed: 20.12.24).
17. Kurajoh M., Fukumoto S., Yoshida S. et al. Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry. Sci Rep. 2021;11(1):7378. https://doi.org/10.1038/s41598-021-86962-0
18. Zhang M., Cui R., Zhou Y. et al. Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. Toxicology. 2022;483:153387. https://doi.org/10.1016/j.tox.2022.153387
19. Kahnert K., Alter P., Welte T. et al. Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respir Res. 2018;19:110. https://doi.org/10.1186/s12931-018-0815-y.
20. Embarak S., Sileem A. E., Abdrabboh M., Mokhtar A. Serum uric acid as a biomarker for prediction of outcomes of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. Egypt J Bronchol. 2014;8:115–120. https://doi.org/10.4103/16878426.145703.
21. Bartziokas K., Papaioannou A. I., Loukides S. et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J. 2014;43(1):43–53. https://doi.org/10.1183/09031936.00209212.
22. Kobylecki C. J., Vedel-Krogh S., Afzal S. et al. Plasma urate, lung function and chronic obstructive pulmonary disease: a Mendelian randomisation study in 114 979 individuals from the general population. Thorax. 2018;73:748–757. https://dx.doi.org/10.1136/thoraxjnl-2017-210273.
23. Yang H., Wang Z., Xiao S. et al. Association between serum uric acid and lung function in people with and without chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2022;2022:1069– 1080. https://dx.doi.org/10.2147/COPD.S356797.
24. Sahana K., Sivaranjani H. Uric acid: a mirror to the lungs in COPD. J Assoc Physicians India. 2022;70(4):11–2. PMID: 35443464.
25. Sharaf El Din U. A., Salem M. M., Abdulazim D. O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res. 2017;8(5):537–548. https://dx.doi.org/10.1016/j.jare.2016.11.004.
26. Jayashankar C. A., Andrews H. P., Vijayasarathi et al. Serum uric acid and low-density lipoprotein cholesterol levels are independent predictors of coronary artery disease in Asian Indian patients with type 2 diabetes mellitus. J Nat Sci Biol Med. 2016;7(2):161–165. https://doi.org/10.4103/0976-9668.184703.
27. Tscharre M., Herman R., Rohla M. et al. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Atherosclerosis. 2018;270:173–179. https://dx.doi.org/10.1016/j.atherosclerosis.2018.02.003.
28. Magnoni M., Berteotti M., Ceriotti F. et al. Serum uric acid on admission predicts in-hospital mortality in patients with acute coronary syndrome. Int J Cardiol. 2017;240:25–29. https://doi.org/10.1016/j.ijcard.2017.04.027.
29. Eckner D., Popp S., Wicklein S., Pauschinger M. Acute coronary syndrome in older people. Z Gerontol Geriatr. 2018;51(4):461–475. (In German) https://dx.doi.org/10.1007/s00391-018-1411-y.
30. Pagidipati N. J., Hess C. N., Clare R. M. et al. An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. Am Heart J. 2017;187:53–61. https://doi.org/10.1016/j.ahj.2017.02.023.
31. Guo G., Huang Z., Wang S., Chen X. Sex differences in uric acid and NT-proBNP assessments during coronary severity. Medicine (Baltimore). 2020;99(15):e19653. https://dx.doi.org/10.1097/MD.0000000000019653.
32. Spahic E., Hasic S., Kiseljakovic E. et al. Positive correlation between uric acid and C-reactive protein serum level in healthy individuals and patients with acute coronary syndromes. Med Glas (Zenica). 2015;12(2):128–132. https://doi.org/10.17392/821.
33. Saito Y., Kitahara H., Nakayama T. et al. Relation of elevated serum uric acid level to endothelial dysfunction in patients with acute coronary syndrome. J Atheroscler Thromb. 2019;26(4):362–7. https://doi.org/10.5551/jat.45179.
34. Kobayashi N., Hata N., Tsurumi M. et al. Relation of coronary culprit lesion morphology determined by optical coherence tomography and cardiac outcomes to serum uric acid levels in patients with acute coronary syndrome. Am J Cardiol. 2018;122(1):17–25. https://dx.doi.org/10.1016/j.amjcard.2018.03.022.
35. Karim B., Nasution S. A., Wijaya I. P., Harimurti K. Hyperuricemia as a risk factor of major adverse cardiac events in patients with acute coronary syndrome: a retrospective cohort study. Acta Med Indones. 2015;47(4):320–5. PMID: 26932701.
36. Lopez-Pineda A., Cordero A., Carratala-Munuera C. et al. Hyperuricemia as a prognostic factor after acute coronary syndrome. Atherosclerosis. 2018;269:229–235. PMID: 29407598. https://dx.doi.org/10.1016/j.atherosclerosis.2018.01.017.
37. Cuifang He, Peihuan Lin, Wenbin Liu, Kuifa Fang. The prognostic value of hyperuricemia in patients with acute coronary syndrome: a meta-analysis. Eur J Clin Invest. 2019;49(4):e13074. PMID: 30701529. https://doi.org/10.1111/eci.13074.
Review
For citations:
Bruchkus E.A., Kulik V.V., Kirpichnikov S.I., Shaporova N.L. Uric acid level as a risk factor for the adverse course of COPD and acute coronary syndrome (ACS). New St. Petersburg Medical Records. 2024;(4):20-25. (In Russ.) https://doi.org/10.24884/1609-2201-2024-103-4-20-25
Views:
97
Email this article 